ISSN: 2167-065X

Pharmacologie clinique et biopharmaceutique

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Revolutionizing Drug Discovery: The Role of Artificial Intelligence

Christo Molloy

The field of drug discovery has long been a challenging and time-consuming process, often requiring years of research and testing to develop new treatments for diseases. However, recent advancements in artificial intelligence (AI) have the potential to revolutionize the drug discovery process and significantly accelerate the development of new therapeutics. AI-based drug discovery methods involve using machine learning algorithms to analyze large datasets of biological and chemical information. This approach can quickly identify potential drug candidates and predict their efficacy, reducing the need for expensive and time-consuming experimental testing. One example of AI-based drug discovery is the use of deep learning algorithms to analyze the three-dimensional structure of proteins and predict how small molecules could bind to them. This approach has already led to the discovery of new drug candidates for diseases such as Alzheimer's and cancer.